Sequentially, we evaluated the targetable variations detected ability in different samples, including EGFR, ALK, BRAF V600E, KRAS, MET ex14 skipping, RET, ROS1, ERBB2, which have high evidence in lung cancer. This evidence concerns the gene MET and lung cancer.